Literature DB >> 27063404

A truncated splice variant of human lysyl oxidase-like 2 promotes migration and invasion in esophageal squamous cell carcinoma.

Hai-Ying Zou1, Guo-Qing Lv1, Li-Hua Dai1, Xiu-Hui Zhan1, Ji-Wei Jiao1, Lian-Di Liao2, Tai-Mei Zhou3, Chun-Quan Li4, Bing-Li Wu1, Li-Yan Xu5, En-Min Li6.   

Abstract

Lysyl oxidase-like 2 (LOXL2) is a member of the lysyl oxidase family, which plays an important role in extracellular matrix protein biosynthesis and tumor progression. In the present study, we identified a novel splice variant, LOXL2Δ72, which encodes a peptide having the same N- and C-termini as wild-type LOXL2 (LOXL2WT), but lacks 72 nucleotides encoding 24 amino acids. LOXL2Δ72 had dramatically reduced enzymatic activity, and was no longer secreted. However, LOXL2Δ72 promoted greater cell migration and invasion than LOXL2WT. Furthermore, a dual luciferase reporter assay indicated that LOXL2Δ72 activates distinct signal transduction pathways compared to LOXL2WT, consistent with cDNA microarray data showing different expression levels of cell migration- and invasion-related genes induced following over-expression of each LOXL2 isoform. In particular, LOXL2Δ72 distinctly promoted esophageal squamous cell carcinoma (ESCC) cell migration via up-regulating the C-C motif chemokine ligand 28 (CCL28). Our results suggest that the new LOXL2 splice variant contributes to tumor progression by novel molecular mechanisms different from LOXL2WT.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cell invasion; Cell migration; Lysyl oxidase activity; Lysyl oxidase-like 2; Splice variant

Mesh:

Substances:

Year:  2016        PMID: 27063404     DOI: 10.1016/j.biocel.2016.04.003

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  7 in total

1.  Identification of lncRNA-associated differential subnetworks in oesophageal squamous cell carcinoma by differential co-expression analysis.

Authors:  Wei Liu; Cai-Yan Gan; Wei Wang; Lian-Di Liao; Chun-Quan Li; Li-Yan Xu; En-Min Li
Journal:  J Cell Mol Med       Date:  2020-03-12       Impact factor: 5.310

2.  Alterations of RNA splicing patterns in esophagus squamous cell carcinoma.

Authors:  Jiyu Ding; Chunquan Li; Yinwei Cheng; Zepeng Du; Qiuyu Wang; Zhidong Tang; Chao Song; Qiaoxi Xia; Wenjing Bai; Ling Lin; Wei Liu; Liyan Xu; Enmin Li; Bingli Wu
Journal:  Cell Biosci       Date:  2021-02-09       Impact factor: 7.133

3.  CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion.

Authors:  Junhee Park; Xianglan Zhang; Sun Kyoung Lee; Na-Young Song; Seung Hwa Son; Ki Rim Kim; Jae Hoon Shim; Kwang-Kyun Park; Won-Yoon Chung
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

4.  Specific gene expression profiles are associated with a pathologic complete response to neoadjuvant therapy in esophageal adenocarcinoma.

Authors:  Patrick J McLaren; Anthony P Barnes; Willy Z Terrell; Gina M Vaccaro; Jack Wiedrick; John G Hunter; James P Dolan
Journal:  Am J Surg       Date:  2017-03-27       Impact factor: 2.565

5.  The interaction of lncRNA EZR-AS1 with SMYD3 maintains overexpression of EZR in ESCC cells.

Authors:  Xiao-Dan Zhang; Guo-Wei Huang; Ying-Hua Xie; Jian-Zhong He; Jin-Cheng Guo; Xiu-E Xu; Lian-Di Liao; Yang-Min Xie; Yong-Mei Song; En-Min Li; Li-Yan Xu
Journal:  Nucleic Acids Res       Date:  2018-02-28       Impact factor: 16.971

6.  RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes.

Authors:  Rui-Jie Zeng; Chun-Wen Zheng; Jing-E Gu; Hai-Xia Zhang; Lei Xie; Li-Yan Xu; En-Min Li
Journal:  Mol Oncol       Date:  2019-07-27       Impact factor: 6.603

7.  Combined detection of IL-6 and IL-8 is beneficial to the diagnosis of early stage esophageal squamous cell cancer: a preliminary study based on the screening of serum markers using protein chips.

Authors:  Qiang Tong; Xiao-Long Wang; Sheng-Bao Li; Gong-Li Yang; Shu Jin; Zi-Ye Gao; Xiao-Bo Liu
Journal:  Onco Targets Ther       Date:  2018-09-12       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.